This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic CRT Devices Improve Therapy Delivery, Cut Costs
by Zacks Equity Research
Medtronic plc (MDT) recently announced positive data on cardiac resynchronization therapy (CRT) devices within its Cardiac and Vascular segment.
Medtronic Posts Positive Result on Reactive ATP, Grows in AF
by Zacks Equity Research
Medtronic's (MDT) Reactive ATP therapy slows the progression of AF in patients who are being implanted with cardiac devices.
Medtronic Resource Centre Opens for Diabetic People in Canada
by Zacks Equity Research
Medtronic plc (MDT) announced that its subsidiary has opened its first Canadian Medtronic Resource Centre to serve diabetic patients in Surrey BC and nearby.
Medtronic Launches MiniMed 670G to Better Manage Diabetes
by Zacks Equity Research
Medtronic plc (MDT) commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients.
Medtronic SureTune3 Obtains Health Canada License for DBS
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of Health Canada license for SureTune 3 software for deep brain stimulation (DBS).
Company News for May 26, 2017
by Zacks Equity Research
Companies in the News are: MDT,SIG,HRL,GES
Medtronic (MDT) Tops Q4 Earnings, Sales on Balanced Growth
by Zacks Equity Research
Medtronic plc's (MDT) fourth-quarter fiscal 2017 adjusted earnings per share came in at $1.33, a couple of cents ahead of the Zacks Consensus Estimate.
Medtronic Puts First Patient in IN.PACT AV Access DCB Study
by Zacks Equity Research
Medtronic plc (MDT), announced the first patient enrollment under its IN.PACT AV Access Drug-Coated Balloon (DCB) study for patients with end-stage renal disease (ESRD).
Medtronic (MDT) Beats on Q4 Earnings & Revenues Estimates
by Zacks Equity Research
Currently, Medtronic has a Zacks Rank #4 (Sell) but that could change following its positive fourth-quarter fiscal 2017 earnings report which has just released.
Medtronic (MDT) Q4 Earnings: Stock Likely to Beat Again?
by Zacks Equity Research
We expect Ireland-based medical device major Medtronic plc (MDT) to beat expectations when it reports its fourth-quarter and fiscal 2017 results on May 25, before the opening bell.
HRL vs. SAFM: Which Stock Looks Better Ahead of Earnings?
by Swarup Gupta
With Hormel Foods and Sanderson Farms scheduled to report on May 25, this may be a good time to consider which is a better stock.
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
by Zacks Equity Research
Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.
Medtronic's MyCareLink Data on Older Patients Found Positive
by Zacks Equity Research
Medtronic plc (MDT) recently released favorable data on its app-based remote cardiac monitoring.
Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.
The Zacks Analyst Blog Highlights: Comcast, Medtronic, FedEx, Praxair and Twitter
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Medtronic, FedEx, Praxair and Twitter
Top Research Reports for Today: CMCSA, MDT, FDX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Medtronic (MDT) and FedEx (FDX).
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017
Medtronic Initiates Product Recall, A Drag on Neurosurgery
by Zacks Equity Research
Medtronic plc. (MDT) has initiated a voluntary product recall of all unused units of its StrataMR adjustable valves and shunts based on an increase in the product complaint rate.
Medtronic (MDT) Less-Invasive HVAD Pump Results Positive
by Zacks Equity Research
Medtronic plc (MDT), a leading name in medical device space, recently presented preliminary results from its HVAD LATERAL study.
Medtronic HVAD System Results Positive for Long-Term Therapy
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently released results of its ENDURANCE Supplemental trial in regard to HVAD System.
United Therapeutics Tanks, Remodulin Pump Launch Delayed
by Zacks Equity Research
United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin
Medtronic's (MDT) CoreValve Evolut Pro Receives FDA Approval
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve.
Medtronic's Positive 2-Year SURTAVI Data Boosts Corevalve
by Zacks Equity Research
Medtronic plc (MDT) has released the first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial.
Mazor Robotics-Medtronic's Mazor X Partnership Strengthens
by Zacks Equity Research
Mazor Robotics (MZOR) recently announced that its strategic partnership with Medtronic Plc. (MDT) for the commercialization and co-promotion of Mazor X platform, an innovative guidance system for spine surgery, is going strong.
Medtronic's Melody TPV Wins FDA for Less-Invasive Treatment
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for Melody Transcatheter Pulmonary Valve for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed.